Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research
Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research
复制标题
DOI：
10.1016/s1470-2045(17)30726-x
复制
发表时间：
2018-02-01
期刊：
影响因子：
51.1
通讯作者：
Cazier，Jean-Baptiste
中科院分区：
文献类型：
--
作者：
Sundar，Sudha;Khetrapal-Singh，Poonam;Cazier，Jean-Baptiste
总的来说，乳腺癌、宫颈癌、卵巢癌和子宫癌占印度女性癌症的70%以上。女性癌症患者临床表现的明显差异表明癌症生物学和遗传学存在潜在差异。在印度，乳腺癌和卵巢癌的发病高峰年龄（45-50岁）似乎比高收入国家（50 - 60岁）早10年。通过研究了解这些差异，制定针对印度人口的诊断、筛查、预防和治疗框架，对于改善印度妇女的健康至关重要。自2001年人类基因组测序以来，大规模平行测序等先进技术的应用改变了人们对癌症遗传和环境驱动因素的理解。如何利用先进技术，以适合一个拥有12亿人口的国家的规模和预算提供保健解决方案？需要哪些研究项目来回答印度特有的问题，并利用这些技术建立创新解决方案的能力？为了回答这些问题，我们召集了一个与主要利益相关者一起讨论这些问题的研讨会。在这篇系列论文中，我们强调了在解决印度日益增长的癌症负担方面面临的挑战，讨论了正在进行的基因组学研究和基础设施的发展，并提出了印度未来癌症研究的关键优先事项。
Cumulatively, breast, cervical, ovarian, and uterine cancer account for more than 70% of cancers in women in India. Distinct differences in the clinical presentation of women with cancer suggest underlying differences in cancer biology and genetics. The peak age of onset of breast and ovarian cancer appears to be a decade earlier in India (age 45–50 years) than in high-income countries (age >60 years). Understanding these differences through research to develop diagnosis, screening, prevention, and treatment frameworks that ar e specific to the Indian population are critical and essential to improving women's health in India. Since the sequencing of the human genome in 2001, applications of advanced technologies, such as massively parallel sequencing, have transformed the understanding of the genetic and environmental drivers of cancer. How can advanced technologies be harnessed to provide health-care solutions at a scale and to a budget suitable for a country of 1·2 billion people? What research programmes are necessary to answer questions specific to India, and to build capacity for innovative solutions using these technologies? In order to answer these questions, we convened a workshop with key stakeholders to address these issues. In this Series paper, we highlight challenges in tackling the growing cancer burden in India, discuss ongoing genomics research and developments in infrastructure, and suggest key priorities for future research in cancer in India.